Sunday, 20 September 2026European Markets

MEMSCAP REGPT Stock Over 27% Up In The Last 21 Sessions

Loading stream...

(vianews) - shares of memscap regpt (cac 40: mems.pa) rose by a staggering 27.42% in 21 sessions from €3.1 to €3.95 at 17:05 est on monday, after four successive sessions in a row of losses. cac 40 is dropping 0.91% to €7,204.79, after two successive sessions in a row of gains.

memscap regpt's last close was €3.90, 2.5% under its 52-week high of €4.00.

about memscap regpt

memscap, s.a. provides micro-electro-mechanical systems (mems) based solutions for aerospace and defense, optical communications, medical and biomedical, and it/consumer markets worldwide. the company offers pressure sensors, pressure transducers, and pressure switches for various applications, such as air data computers, cabin pressure, engine control, altimeters, barometers, cockpit instruments, and air data test sets. it also provides gold coated and titanium-based pressure transducers, plastic domes, line-sets, and related accessories; and magnetic switches/relays, as well as supplies implantable pressure sensors for spinal pressure monitoring, abdominal aortic aneurism, etc. in addition, the company supplies optical mems chips for variable optical attenuators in optical telecommunication markets; and provides the multi-user mems processes (mumps) comprising polymumps, soimumps, and piezomumps, as well as mumps-plus and post processing services. further, it offers custom products, including wafers, mems dies, and wafer level packaged devices; and manufacturing services, as well as prototyping services. the company sells its products and services to fortune 500 companies, high-technology industries, research institutes, and universities. memscap, s.a. was founded in 1997 and is headquartered in crolles, france.

more news about memscap regpt (mems.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com